DDInter1003 DDInter1676
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ixekizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ixekizumab may lead to a major life threatening interaction when taken with Etanercept
Ixekizumab may lead to a major life threatening interaction when taken with Upadacitinib